SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SOLIGENIX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.34−0.01 (-2.66%)
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
SOLIGENIX, INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialized BioTherapeutics | – | – | – | – | – | – | $119.37K | $290.63K | $290.63K | $356.79K | $395.12K | – | – | – |
| Public Health Solutions | – | – | – | – | – | – | – | – | – | – | $444.24K | $704.82K | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public Health Solutions | -$30.81K | -$32.19K | -$88.77K | -$155.04K | -$210.00K | -$267.82K | -$254.58K | -$175.55K | -$142.76K | -$82.96K | -$36.53K | $131.17K | -85.3% |
| Specialized BioTherapeutics | -$6.22M | -$6.89M | -$6.98M | -$7.25M | -$6.55M | -$5.28M | -$4.37M | -$2.56M | -$2.43M | -$2.76M | -$2.81M | -$4.45M | -5.1% |
By product or service
By region
From the segment and revenue-disaggregation notes of Soligenix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.